The Usage of Chitosan-Functionalized Mesoporous Silica Nanoparticles as a pH Sensitive Mechanism for Drug Delivery in Cancer Treatment

Aidan Maxwell
First Year Student (B.Sc. Nanoscience)

College of Physical and Engineering Science, University of Guelph, CANADA

In the process of eliminating a tumor, traditional cancer therapy is typically ineffective at minimizing the number of healthy cells that are damaged or killed, and can often lead to serious side-effects on the patient’s health (Abe et al. 2005; Liu et al. 2015; Khemtong et al. 2009). In recent years however, studies have demonstrated that the controlled release of drugs such as doxorubicin (DOX) through the usage of nanoparticles has the potential to significantly decrease the severity of these side-effects (Liu et al. 2015; Tang et al. 2011). Certain nanoparticles can be loaded with medication and modified to release this medication in response to a stimulus (such as a certain pH) in order to ensure only cancerous cells are primarily exposed to the medication, thus minimizing the quantity of healthy cells that are affected (Yan et al. 2010; Zheng et al. 2012; Fang et al. 2014). This has the potential to revolutionize the field of medicine and treatment of not only cancer, but multitudes of other diseases.

Recently, mesoporous silica nanoparticles (MSNs) have been investigated intensively as a candidate for controlled drug delivery to treat a variety of diseases, including cancer (Deng et al. 2011). MSNs are a spherical variation of silica particles that are roughly 300 nanometres across and contain pores with variable diameters of anywhere between 2 and 50 nanometres (Gan et al. 2014). One of the main advantages that MSNs bring to cancer therapy is their large surface area and high porosity, the aspect of the nanoparticles that primarily facilitates drug loading (Liu et al. 2015). Furthermore, the variability in pore diameter of MSNs allows for loading of drugs of many different sizes as well.

Additional properties of MSNs that make them a highly practical candidate for delivery of cancer-treating drugs include: low toxicity, tunable pore size, modifiable surface, biodegradability, and high chemical and thermal stability (Liu et al. 2015; Pourjavadi and Tehrany 2013). The biocompatibility of MSNs both in vitro and in vivo has also been illustrated by several recent studies. In addition, reports on the biodistribution and circulation properties of MSNs administered in animals by intravenous injection have highlighted the promise of these porous, multifunctional nanoparticles for in vivo medical applications (Zhao et al. 2009).

Several methods exist for synthesizing and subsequently loading drugs
onto MSNs and they usually involve exposure to a range of different chemicals and treatments at particular temperatures and pH values. The most common method for MSN synthesis is the sol-gel method, described as the formation of an oxide network through polycondensation reactions of a molecular precursor in a liquid (Liu et al. 2015).

However, due to the relatively low circulation life of the MSN-drug complex, simply loading the drugs onto MSNs is ineffective for their targeted release in vivo. This is because there is nothing preventing the loaded drugs from dissociating from the nanoparticles, especially after being exposed to bodily fluids (Pourjavadi and Tehrany 2013). It is for this reason that MSNs are functionalized, or coated, with other molecules that respond to stimuli, controlling the release of the medication. Chitosan proves to be a very suitable candidate to fill this role (Liu et al. 2015).

Chitosan, a linear polysaccharide, plays the role of a protective coating in chitosan-functionalized MSNs, preventing the loaded drugs from being prematurely released in vivo (Yan et al. 2010). Additionally, it acts as a control that triggers the release of the drugs in response to a pH stimulus. This stimulus occurs because of a change in pH between bodily fluids and cancer cells; the normal body fluid pH is about 7.4, while the pH value at cancer cells is generally 6.8 or lower (Liu et al. 2015). Once the MSN/drug/chitosan complex reaches the tumor in the patient’s body, the slightly more acidic pH of the cancerous cells will initiate the dissociation of chitosan, thereby enabling the drugs to be released (Yan et al. 2010).

Liu et al. (2015) loaded ibuprofen onto MSNs, functionalized the MSNs with chitosan and tested the drug release mechanism in vitro on various pH levels. It was found that the drug delivery system was very effective; the outer layer of chitosan dissolved, thereby enabling the ibuprofen to be released under specific pH conditions. Furthermore, Fang et al. (2014) found that when using doxorubicin with chitosan-functionalized MSNs, the release amount of DOX was ~60% at a pH of 5.5 while it was ~15% at pH 7.4. This evidence reinforces the suitability of MSNs as candidates for drug carriers used for targeted drug release in cancer cells with an acidic pH environment.

Chitosan-functionalized MSNs have the potential to revolutionize the treatment of cancer by localizing drug administration and thereby minimizing damage caused to non-cancerous cells (Yan et al. 2010; Zheng et al. 2012; Fang et al. 2014). The porous nanoparticles, coated with chitosan, can be loaded with drugs such as doxorubicin, as well as many other drugs of various sizes, and released in vitro via intravenous injection (Liu et al. 2015; Zhao et al. 2009). Once the MSN/drug/chitosan complex reaches cancerous cells, the chitosan dissolves in response to the slightly acidic pH, delivering the drug directly to the tumor (Liu et al. 2015; Fang et al. 2014). This direct delivery of medication along with the low toxicity and high biocompatibility of mesoporous silica nanoparticles combine to provide a highly effective drug delivery
mechanism with fewer side-effects on the health of patients compared to conventional methods (Abe et al. 2005; Zheng et al. 2012). Chitosan-functionalized MSNs are the future of drug delivery for the treatment of cancer, and may hold promise for other diseases as well.

References


